Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin: A Randomized Double-blind Clinical Trial | Myasthenia Gravis | JAMA Neurology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Gajdos  PChevret  SToyka  K Intravenous immunoglobulin for myasthenia gravis.  Cochrane Database Syst Rev 2003;2CD002277Google Scholar
Gajdos  PChevret  SClair  BTranchant  CChastang  CMyasthenia Gravis Clinical Study Group, Clinical trial of plasma exchange and high-dose immunoglobulin in myasthenia gravis.  Ann Neurol 1997;41789- 796PubMedGoogle ScholarCrossref
Laird  NMWare  JH Random-effects models for longitudinal data.  Biometrics 1982;38963- 974PubMedGoogle ScholarCrossref
Zeger  SLLiang  KY Longitudinal data analysis for discrete and continuous outcomes.  Biometrics 1986;42121- 130PubMedGoogle ScholarCrossref
Sharshar  TChevret  SMazighi  M  et al.  Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis.  J Neurol 2000;247286- 290PubMedGoogle ScholarCrossref
Original Contribution
November 2005

Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin: A Randomized Double-blind Clinical Trial

Author Affiliations

Author Affiliations: Medical Intensive Care Unit, Raymond Poincaré Teaching Hospital, Assistance publique–Hôpitaux de Paris, Garches (Drs Gajdos and Clair); Neurology Department, Strasbourg Civilian Hospitals, Strasbourg (Dr Tranchant); Neurology Department (Dr Bolgert) and Institute de Myologie (Dr Eymard), Salpêtrière Teaching Hospital, Assistance publique–Hôpitaux de Paris, Paris, Neurology Department, Roger Salengro Teaching Hospital, Lille (Dr Stojkovic); Neurology Department, La Timone Teaching Hospital, Marseille (Dr Attarian); and Biostatistics and Medical Informatics Department, Saint-Louis Teaching Hospital, Assistance publique–Hôpitaux de Paris, U717-INSERM, Paris (Dr Chevret), France.

Arch Neurol. 2005;62(11):1689-1693. doi:10.1001/archneur.62.11.1689

Background  The optimal dose of intravenous immunoglobulin (IVIG) in acute exacerbation of myasthenia gravis remains unknown. Increasing the treatment duration might provide added efficacy.

Objective  To determine the optimal dose of IVIG for treating myasthenia gravis exacerbation.

Design  Randomized double-blind placebo-controlled multicenter trial designed to demonstrate superiority of the 2 g/kg dose over the 1 g/kg dose of IVIG, conducted between November 13, 1996, and October 26, 2002.

Participants  One hundred seventy-three patients aged 15 to 85 years with acute exacerbation of myasthenia gravis.

Intervention  Participants were randomly assigned to receive 1 g/kg of IVIG on day 1 and placebo on day 2 (group 1) vs 1 g/kg of IVIG on 2 consecutive days (group 2).

Main Outcome Measure  Improvement in the myasthenic muscular score after 2 weeks.

Results  The mean improvements in the myasthenic muscular scores after 2 weeks were 15.49 points (95% confidence interval, 12.09-18.90 points) in group 1 and 19.33 points (95% confidence interval, 15.82-22.85 points) in group 2. However, the difference between the 2 groups was not significant (effect size, 3.84 [95% confidence interval, −1.03 to 8.71]; P = .12).

Conclusion  This trial found no significant superiority of 2 g/kg over 1 g/kg of IVIG in the treatment of myasthenia gravis exacerbation.